Key result
Peak creatinine during CRS1 decongestion linked to ~49% higher 10-day MAKE risk per /dL.
Why the study?
Mild increases in serum creatinine during decongestive therapy for type 1 cardiorenal syndrome are often attributed to functional hemodynamic changes, but the prognostic value of more severe elevations was uncertain.
Does severe serum creatinine elevation during decongestive therapy increase the risk of major adverse kidney events in hospitalized patients with type 1 cardiorenal syndrome?
Cohort (n=165)
Does severe serum creatinine elevation during decongestive therapy increase the risk of major adverse kidney events in hospitalized patients with type 1 cardiorenal syndrome?
Severe serum creatinine elevations (>3–4 mg/dL) during decongestion in type 1 cardiorenal syndrome are not benign and independently predict higher rates of major adverse kidney events, primarily driven by kidney replacement therapy.
Answers are grounded in this paper and cite their sources.
Severe creatinine rises during decongestion signal higher MAKE risk; hypothesis-generating and should not yet change practice in cardiorenal syndrome.
Background In type 1 cardiorenal syndrome (CRS1), mild increases in serum creatinine (sCr) during decongestive therapy are common and often attributed to functional hemodynamic changes. However, the prognostic value of more severe sCr elevations remains uncertain. Methods We conducted a prospective cohort study of hospitalized patients with CRS1, categorized by the presence or absence of effective clinical decongestion. The primary outcome was the occurrence of major adverse kidney events at 10 days (MAKE10), defined as death, initiation of kidney replacement therapy (KRT), or a ≥25% decline in estimated glomerular filtration rate (eGFR). Secondary outcomes included MAKE at 30 and 30–90 days. Results A total of 165 patients were included (median age 65.5 years; 46% female). Mean sCr increase from minimum to peak during decongestion was 2.1±1.8 mg/dL, with 94% showing ≥0.5 mg/dL increase. MAKE10 occurred in 84% of patients. Peak sCr was independently associated with MAKE10 (OR 1.49 per 1 mg/dL; 95% CI 1.05–2.13; p=0.02) and MAKE30–90 (OR 1.33; 95% CI 1.09–1.63; p=0.005), especially when exceeding 3–4 mg/dL. This was mainly driven by higher KRT initiation rates. Peak sCr was not independently associated with mortality; however, mortality was significantly higher in patients with substantial sCr elevation and no decongestion (p=0.042). Conclusion Severe sCr elevations during CRS1 decongestion are not uniformly benign. While mild increases may reflect expected functional changes, elevations beyond 3–4 mg/dL are associated with greater risk of MAKE, particularly due to increased KRT requirement.
No takes yet. Share an insight, caveat, or question.
Medina et al. (2026) conducted a cohort in Type 1 cardiorenal syndrome (CRS1) (n=165). Peak serum creatinine elevation during decongestion vs. Presence vs. absence of effective clinical decongestion was evaluated on Major adverse kidney events at 10 days (MAKE10), defined as death, initiation of kidney replacement therapy (KRT), or a ≥25% decline in estimated glomerular filtration rate (eGFR) (OR 1.49 per 1 mg/dL, 95% CI 1.05-2.13, p=0.02). Peak serum creatinine during CRS1 decongestion was independently associated with 10-day major adverse kidney events.
Synapse has enriched 10 related papers. Consider them for comparative context: